Impact of intensive care unit (ICU) drug use on hospital costs: A descriptive analysis, with recommendations for optimizing ICU pharmacotherapy

ObjectiveTo determine the cost impact of intensive care unit (ICU) drug use on a hospital’s total drug expense and to compare ICU pharmacy resource utilization with resource utilization of other hospital departments that provided services to the ICU. Additionally, to suggest strategies, based on these methods and results, to optimize ICU drug use. MethodsFinancial transactions for all ICU patients (n = 23,107) treated during fiscal years 1999–2002 were retrieved from the hospital’s data repository. ICU drug costs were calculated both as the percentage of total drug costs for each fiscal year and adjusted for hospital volume (ICU patient days). ICU department charges were calculated as a percentage of total ICU charges and analyzed by simple descriptive statistics (mean ± sd). Drug utilization was retrieved for those patients accounting for the highest percentage of ICU pharmacy charges. Main ResultsICU drug costs accounted for 38.4% (±4.1% sd) of the total drug costs and have increased at a rate greater than non-ICU drug costs (12% vs. 6%). ICU pharmacy charges accounted for an average of 11.1% (±9.2% sd) of the total ICU charges, ranking as the fourth most costly of ICU charges. Both costly and highly used ICU therapies were identified for focus on cost-effectiveness analyses or application of an evidence-based drug use and disease state management program model to ICU pharmacotherapy. ConclusionsICU drug therapies have a significant impact on hospital costs, and effective clinical informatics services and multidisciplinary collaboration programs are necessary to optimize ICU pharmacotherapy.

[1]  M. Saul,et al.  The cost of caring for end-stage kidney disease patients: an analysis based on hospital financial transaction records. , 1998, Journal of the American Society of Nephrology : JASN.

[2]  L. Thijs,et al.  Continuous infusion of lorazepam versus medazolam in patients in the intensive care unit: sedation with lorazepam is easier to manage and is more cost-effective. , 1999, Critical care medicine.

[3]  R. Barrientos-Vega,et al.  Prolonged sedation of critically ill patients with midazolam or propofol: impact on weaning and costs. , 1997, Critical care medicine.

[4]  D. Bates,et al.  Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. , 1999, JAMA.

[5]  D. Bates,et al.  The Costs of Adverse Drug Events in Hospitalized Patients , 1997 .

[6]  J. Bigger,et al.  NEW DRUGS. , 1979, Canadian Medical Association journal.

[7]  N. Shah,et al.  Projecting future drug expenditures--2002. , 2002, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[8]  M. Rudis,et al.  Economic impact of prolonged motor weakness complicating neuromuscular blockade in the intensive care unit. , 1996, Critical care medicine.

[9]  J. Tumlin,et al.  Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion: a pilot trial in the prevention of contrast nephropathy. , 2002, American heart journal.

[10]  A. Anis,et al.  Economic Evaluation of Propofol for Sedation of Patients Admitted to Intensive Care Units , 2002, Anesthesiology.

[11]  M. F. Mascia,et al.  Pharmacoeconomic impact of rational use guidelines on the provision of analgesia, sedation, and neuromuscular blockade in critical care , 2000, Critical care medicine.

[12]  G A Colditz,et al.  Cost-Effectiveness and Cost-Benefit Analyses in the Medical Literature , 1992, Annals of Internal Medicine.

[13]  D. Hussar.  New drugs of 2000. , 2001, Journal of the American Pharmaceutical Association.

[14]  G. Carrasco,et al.  Propofol vs midazolam in short-, medium-, and long-term sedation of critically ill patients. A cost-benefit analysis. , 1993, Chest.

[15]  John K. Vries,et al.  The medical archival system: An information retrieval system based on distributed parallel processing , 1991, Inf. Process. Manag..

[16]  J. Devlin,et al.  The Effect of ICU Sedation Guidelines and Pharmacist Interventions on Clinical Outcomes and Drug Cost , 1997, The Annals of pharmacotherapy.

[17]  M. Rudis,et al.  Position Paper on Critical Care Pharmacy Services , 2000 .

[18]  S. Skledar,et al.  Implementation of a drug-use and disease-state management program. , 2000, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[19]  D Teres,et al.  Critical care delivery in the intensive care unit: Defining clinical roles and the best practice model , 2001, Critical care medicine.

[20]  J. Rotschafer,et al.  Intensive care unit antimicrobial resistance and the role of the pharmacist , 2001, Critical care medicine.

[21]  Mark S. Roberts,et al.  Understanding costs and cost-effectiveness in critical care: report from the second American Thoracic Society workshop on outcomes research. , 2002, American journal of respiratory and critical care medicine.

[22]  P. Pierpaoli.  The rising cost of pharmaceuticals: a director of pharmacy's perspective. , 1993, American journal of hospital pharmacy.

[23]  L. Sanchez.  How to Evaluate and Interpret Outcome Studies , 2000 .

[24]  D. Bates,et al.  Preventable adverse drug events in hospitalized patients: a comparative study of intensive care and general care units. , 1997, Critical care medicine.

[25]  L. Sanchez,et al.  Interpretation of "cost-effective" and soundness of economic evaluations in the pharmacy literature. , 1991, American journal of hospital pharmacy.

[26]  A. Grizzle,et al.  Drug-related morbidity and mortality: updating the cost-of-illness model. , 2001, Journal of the American Pharmaceutical Association.

[27]  J. Dasta,et al.  Efforts of pharmacy to reduce antibiotic resistance. , 1996, New horizons.

[28]  Robert M. Losee,et al.  An analytic measure predicting information retrieval system performance , 1991, Inf. Process. Manag..

[29]  S. Wilson.  Methods for the economic evaluation of health care programmes , 1987 .

[30]  D. Nicolau,et al.  Cost‐Effectiveness of Ceftazidime by Continuous Infusion versus Intermittent Infusion for Nosocomial Pneumonia , 2001, Pharmacotherapy.

[31]  T. Similowski,et al.  Continuous versus Intermittent Infusion of Vancomycin in Severe Staphylococcal Infections: Prospective Multicenter Randomized Study , 2001, Antimicrobial Agents and Chemotherapy.